Liryc’s team appeared on Times Square screens on the occasion of Acutus Medical becoming a public company trading on Nasdaq.

Liryc has recently contributed to the assessment of the new cardiac mapping system developed by Acutus Medical for Ventricular arrhythmias, a major contributor to sudden cardiac death responsible for 350,000 deaths every year in Europe.

This collaboration is a steppingstone to a mutually exciting and fruitful long-term relationship. Looking forward to work together on advanced tools and procedures in the treatment of arrhythmias.